Transformative Healthcare Instrument 2026

MODERATE Tx General

Strategy Notes

The venture's AI-driven drug resistance prediction aligns well with EIT Health's focus on innovative healthcare solutions. The €300k–€500k non-dilutive funding is ideal for pre-seed stage, and the EU geography matches the founder's target. However, the programme likely requires incorporation, which the venture has not yet completed.

Key Materials

—

Your Notes

Status & Deadline

Status: INELIGIBLE
Deadline: 2026-06-24
Cycle: —
Amount: €300,000 - €500,000
Type: grant
URL: Apply

Update Status

Log Application

AI Pipeline

Research Programme Generate Draft

Status History

2026-07-30 OPEN → INELIGIBLE · The programme requires the applicant to be a private company (SME) with at least 4 full-time equivalent employees and a minimum total equity investment of €2,000,000 within the previous 36 months. Eniola is an independent researcher with no incorporated company, no employees, and no equity investment.